Efficacy and Safety of SAR156597 in the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-blind, Placebo-controlled, 24-week, Proof of Concept Study
Latest Information Update: 04 Feb 2022
At a glance
- Drugs Romilkimab (Primary)
- Indications Diffuse scleroderma
- Focus Proof of concept; Therapeutic Use
- Sponsors Sanofi
- 22 Sep 2020 Results assessing efficacy and safety of romilkimab in patients with early Diffuse Cutaneous Systemic Sclerosis (dcSSc), published in the Annals of the Rheumatic Diseases.
- 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism
- 08 Apr 2019 Status changed from active, no longer recruiting to completed.